(603590)"Beijing Konruns Pharmaceutical Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026
Filed with SSE · Stock code 603590 · · 6 pages · Chinese
Summary by 6ix AI
The meeting will take place at a specified location in Beijing and will include both on-site and online voting options for shareholders. Key agenda items for the meeting include proposals related to the repurchase of certain restricted stocks and amendments to the company's articles of association. Shareholders must register in advance to attend the meeting and can delegate their voting rights to a representative if necessary.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Beijing Konruns Pharmaceutical Co., Ltd. on 6ix
Story so far
Earlier from Beijing Konruns Pharmaceutical
- (603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on the Arbitration Result
- Announcement on Results of the Initial Grant under the 2026 Restricted Share Incentive Plan
- Announcement on Obtaining New Veterinary Drug Registration Certificate
Later from Beijing Konruns Pharmaceutical
- (603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Implementation Results of Share Repurchase and Share Changes
- (603590)"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Receipt of Clinical Trial Approval Notice for KC1086 Combined with Fulvestrant for the Treatment of HR+HER2- Locally Advanced or Metastatic Breast Cancer
Follow Beijing Konruns Pharmaceutical into a list and get an email when it puts out news.
Follow Beijing Konruns Pharmaceutical